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Purpose: Previous studies have suggested an association between [2]proPSA
expression and prostate cancer detection. Less is known about the usefulness of
this marker in following patients with prostate cancer on active surveillance.
Thus, we examined the relationship between [2]proPSA and biopsy results in
men enrolled in an active surveillance program.
Materials and Methods: In 167 men from our institutional active surveillance
program we used Cox proportional hazards models to examine the relationship
between [2]proPSA and annual surveillance biopsy results. The outcome of
interest was biopsy reclassification (Gleason score 7 or greater, more than 2
positive biopsy cores or more than 50% involvement of any core with cancer). We
also examined the association of biopsy results with total prostate specific anti-
gen, %fPSA, [2]proPSA/%fPSA and the Beckman Coulter Prostate Health Index
phi ([2]proPSA/free prostate specific antigen)  (total prostate specific anti-
gen)½).
Results: While on active surveillance (median time from diagnosis 4.3 years), 63
(37.7%) men demonstrated biopsy reclassification based on the previously men-
tioned criteria, including 28 (16.7%) of whom had reclassification based on Glea-
son score upgrading (Gleason score 7 or greater). Baseline and longitudinal
%fPSA, %[2]proPSA, [2]proPSA/%fPSA and phi measurements were signifi-
cantly associated with biopsy reclassification, and %[2]proPSA and phi pro-
vided the greatest predictive accuracy for high grade cancer.
Conclusions: In men on active surveillance, measures based on [2]proPSA
such as phi appear to provide improved prediction of biopsy reclassification
during followup. Additional validation is warranted to determine whether
clinically useful thresholds can be defined, and to better characterize the role of
%[2]proPSA and phi in conjunction with other markers in monitoring patients
enrolled in active surveillance.
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proPSA proenzyme PSA
PSA prostate specific antigen
tPSA total PSA
Submitted for publication September 13,
2011.
Study received institutional review board ap-
proval.
Supported by the Johns Hopkins University Pros-
tate Cancer SPORE (Grant number P50CA58236), the
Prostate Cancer Foundation, the Patana Fund and the
Patrick C. Walsh Prostate Cancer Research Fund.
* Equal study contribution.
† Nothing to disclose.
‡ Correspondence: Department of Pathology,
Johns Hopkins Medical Institutions, 1800 Orleans
St., Sheikh Zayed Tower, B1-1020, Baltimore,
Maryland 21287 (telephone: 410-955-2673; FAX:
410-955-0767; e-mail: lsokoll@jhmi.edu).
§ Financial interest and/or other relationship
with Beckman Coulter, Inc.
See Editorial on page 1070.
For another article on a related
topic see page 1369.
Editor’s Note: This article is the
third of 5 published in this issue
for which category 1 CME creditswatchful waiting
1403.
PROSTATE cancer is the most commonly
diagnosed noncutaneous malignancy
in United States men.1 Although PSA
is widely used in prostate cancer
screening, benign conditions may re-
sult in increased serum PSA which
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cently characterized free PSA iso-
forms may improve the specificity of
PSA. These isoforms include BPSA, a
degraded form increased in benign
prostatic hyperplasia,2 as well as
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[2]proPSA IN ACTIVE SURVEILLANCE1132proPSA, an inactive PSA precursor containing a 7
amino acid pro leader peptide, which has been asso-
ciated with prostate cancer.3 Additional forms of
proPSA that contain truncated leader sequences of
5, 4 or 2 amino acids have also been described.4
Previous studies have demonstrated an increased
proportion of proPSA in prostate cancer tissue and
in the serum of patients with prostate cancer.3,5
Other data have suggested that the proPSA-to-free
PSA ratio (%proPSA) may be superior to total PSA
and percent free PSA in prostate cancer detection in
select subgroups of patients.6,7 An additional appli-
cation of these markers is the recently described
Beckman Coulter Prostate Health Index (phi), which
combines [2]proPSA with free and total PSA.8,9 In
a recent multicenter study phi outperformed total
and %fPSA in the detection of prostate cancer.9
Although the role of proPSA has been examined
in the early detection of cancer, less is known about
its potential applications for patients with prostate
cancer undergoing active surveillance. [2]proPSA
has been associated with prostate cancer aggressive-
ness,9,10 and proPSA has been reported to be specif-
ically associated with high grade (Gleason 7 or
greater) disease among men with PSA between 2
and 4 ng/ml.11 Based on these findings and our ini-
tial results in tissue and serum,12,13 we determined
whether [2]proPSA was associated with biopsy re-
classification in a larger cohort of very low risk pa-
tients enrolled in active surveillance.
MATERIALS AND METHODS
Active Surveillance Program
Since 1995 active surveillance has been offered to patients
who present to our institution with very low risk prostate
cancer,14,15 as defined by Epstein et al16 and endorsed by
the National Comprehensive Cancer Network.17 Enroll-
ment criteria included clinical stage T1c disease, PSA
density less than 0.15 ng/ml/cm3, Gleason score 6 or less,
2 or fewer biopsy cores with cancer and a maximum of 50%
involvement of any core with cancer. All patients provided
written informed consent before enrolling in the institu-
tional review board approved program.
Followup of men in the program included semiannual
PSA measurements (free and total), digital rectal exami-
nation and an annual surveillance biopsy (typically 14-
core, including transition zone biopsies since 2009). Nei-
ther total PSA nor PSA kinetics were used as a trigger for
intervention. Curative intervention was recommended af-
ter evidence of biopsy reclassification (Gleason score 7 or
greater, more than 2 positive biopsy cores or more than
50% involvement of any biopsy core with cancer), taking
into consideration patient preferences and the presence or
absence of comorbidities. In addition, some men request
curative therapy in the absence of biopsy reclassification.Selection of Study Cohort
From 1995 to the initiation of this study 689 men enrolled
in our active surveillance program. Of these men 214 had
a minimum of 2 serum samples (mean 3.5, range 2 to 10)
collected before any of the study biopsies, and available for
PSA and isoforms testing. We excluded 29 men with a
history of finasteride or dutasteride use, 17 men with
unavailable followup biopsy data, and 1 subject with doc-
umented infection at the time of blood draw. The remain-
ing 167 men formed our study population.
Measurement of PSA and Isoforms
Total PSA, free PSA and [2]proPSA (Beckman Coulter
p2PSA) were measured on the Beckman Coulter Access®
2 immunoassay analyzer in samples stored at 80C. The
3 dual monoclonal sandwich assays use Hybritech anti-
bodies and a chemiluminescent detection system. The
[2]proPSA assay has less than 1% cross-reactivity
with other PSA forms. %[2]proPSA was calculated as
([2]proPSA pg/ml/10)/fPSA ng/ml, and phi as ([2]proPSA
pg/ml/fPSA ng/ml)  (tPSA ng/ml)½.
Statistical Analysis
Baseline clinical characteristics and changes from base-
line to last followup were compared using the Wilcoxon
rank sum (Mann-Whitney) test in men who did and those
who did not eventually demonstrate biopsy reclassifica-
tion. Patients who did not experience biopsy reclassifica-
tion were censored at the time of most recent biopsy and
followup was defined as the time from diagnosis to disease
reclassification or censoring.
Separate Cox proportional hazards models were used to
evaluate the association between surveillance biopsy reclas-
sification, and the baseline and longitudinal18 marker mea-
surements. Additional Cox models were used to assess the
relationship between these analytes and biopsy reclassifica-
tion based only on Gleason score upgrading (Gleason score 7
or greater). For longitudinal analyses, if a specimen was not
available for biomarker measurements at the last biopsy,
biomarker results were imputed using the method of last
observation carried forward.19 All models were adjusted for
age, date of diagnosis and PSA density (continuous vari-
ables).
Finally, the concordance index was used to compare the
discrimination of biopsy reclassification among analytes.
The concordance index for longitudinal data was calcu-
lated using the approach described by Newson.20 All anal-
yses were performed using Stata® v11.0.
RESULTS
Of the 167 men included in this analysis median age
at diagnosis was 65.7 years (range 50.6 to 76.1) and
median followup after diagnosis was 4.30 years
(range 0.96 to 10.47). The majority of men were
white. Table 1 compares the characteristics of men
who did or did not demonstrate biopsy reclassifica-
tion. Overall 63 (37.7%) men had biopsy reclassifi-
cation on followup, 29 (17.4%) of whom had Gleason
score upgrading (Gleason score 7 or greater). The
remaining 104 (62.3%) men did not have biopsy re-
classification during followup.
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classification during followup were similar at
baseline with respect to age, %[2]proPSA, pros-
tate volume and median number of biomarker mea-
surements. However, men who demonstrated biopsy
reclassification had a significantly lower initial %fPSA
(p  0.0016), as well as a significantly higher ini-
tial tPSA (p  0.0004), PSA density (p 0.0001),
[2]proPSA/%fPSA (p 0.0001) and phi (p 0.0002).
The duration of followup was significantly longer in
men who did not demonstrate biopsy reclassification
(median 4.78 vs 3.41, p  0.0004).
Cox proportional hazards models for risk of bi-
opsy reclassification are shown in table 2. After ad-
justing for age, date of diagnosis and PSA density,
baseline tPSA was not significantly associated
with biopsy reclassification (p  0.061). However,
risk of reclassification was significantly associated
with lower baseline %fPSA (p  0.002), and higher
%[2]proPSA (p 0.0001), [2]proPSA/%fPSA
(p  0.026) and phi (p 0.0001). Similarly, Cox
models with longitudinal measurements of %fPSA
Table 1. Baseline characteristics of the study population
No. pts
Age:
Mean  SD 65.7
Median (range) 65.8
tPSA (ng/ml):
Mean  SD 4.9
Median (range) 4.6
Prostate vol:
Mean  SD 50.8
Median (range) 48.0
PSA density:
Mean  SD 0.1
Median (range) 0.0
%fPSA:
Mean  SD 20.6
Median (range) 19.4
%[2]proPSA:
Mean  SD 1.5
Median (range) 1.4
[2]proPSA/%fPSA:
Mean  SD 0.7
Median (range) 0.6
phi:
Mean  SD 31.5
Median (range) 29.0
No. biomarker measurements:
Mean  SD 3.3
Median (range) 3.0
Yrs from prostate Ca diagnosis to 1st [2]proPSA:
Mean  SD 1.2
Median (range) 1.1
Yrs from prostate Ca diagnosis to biopsy reclassification or censoring:
Mean  SD 4.4
Median (range) 4.3(p  0.002), %[2]proPSA (p 0.0001), [2]proPSA/%fPSA (p0.005) and phi (p 0.0001) demon-
strated significant associations with biopsy reclas-
sification. Concordance indexes revealed improved
discrimination (predictive accuracy) when baseline
%[2]proPSA, [2]proPSA/%fPSA and phi were in-
all
No Biopsy
Reclassification
Biopsy
Reclassification p Value
104 63
0.7164
.8 65.6  4.5 65.8  5.2
0.6–76.1) 65.8 (55.0–74.9) 66.3 (50.6–76.1)
0.0004
.1 4.5  3.4 5.6  2.3
.40–18.6) 3.86 (0.40–18.6) 5.31 (1.47–13.1)
0.7663
.38 51.95  25.31 49.07  16.34
0–145.3) 49.0 (10.0–145.3) 48.0 (21.9–90.0)
0.0001
.06 0.09  0.06 0.12  0.06
.02–0.39) 0.07 (0.02–0.39) 0.12 (0.04–0.32)
0.0016
.91 22.26  8.03 18.08  7.03
5–41.49) 21.12 (7.92–41.49) 17.52 (5.65–36.71)
0.3587
.54 1.49  0.43 1.63  0.69
.45–4.54) 1.48 (0.52–2.64) 1.48 (0.45–4.54)
0.0001
.48 0.60  0.39 0.90  0.55
.07–2.81) 0.52 (0.07–2.18) 0.76 (0.26–2.81)
0.0002
.42 27.99  10.07 37.45  18.21
–104.62) 26.87 (10.55–64.77) 32.23 (11.14–104.62)
0.067
.54 3.47  1.51 3.11  1.57
(2–10) 3.0 (2–10) 3.0 (2–8)
0.001
.95 1.39  0.92 1.07  0.97
.1–5.91) 1.28 (0.04–5.91) 0.98 (0.1–5.14)
0.0004
.10 4.81  1.93 3.81  2.23
6–10.47) 4.78 (1.00–10.00) 3.41 (0.96–10.47)
Table 2. Cox proportional hazards models and concordance
indices to predict biopsy reclassification using baseline and
longitudinal measurements
Cox Proportional Hazards Models
HR (95% CI) p Value C Index
Baseline:
tPSA 0.90 (0.80–1.00) 0.061 0.630
%fPSA 0.93 (0.89–0.97) 0.002 0.664
%[2]proPSA 2.44 (1.51–3.94) 0.0001 0.651
[2]proPSA/%fPSA 2.13 (1.09–4.16) 0.026 0.652
phi 1.04 (1.02–1.06) 0.0001 0.662
Longitudinal:
tPSA 0.96 (0.88–1.05) 0.366 0.703
%fPSA 0.94 (0.90–0.98) 0.002 0.722
%[2]proPSA 1.92 (1.36–2.73) 0.0001 0.647
[2]proPSA/%fPSA 2.12 (1.25–3.59) 0.005 0.654Over
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[2]proPSA IN ACTIVE SURVEILLANCE1134cluded in the models, or using %fPSA (baseline or
longitudinal) compared to total PSA. For baseline
measures the models that included baseline %fPSA
and phi yielded the highest discriminative accuracy,
while for longitudinal measures %fPSA was the best
discriminant. Notably the scales of measurement dif-
fered for each of these biomarkers. Thus, comparing
themagnitude of the hazard ratio between biomarkers
is not indicative of relative strengths of association.
Table 3 shows Cox proportional hazards models
for the risk of Gleason score upgrading on biopsy
(Gleason score 7 or greater). Baseline and longitu-
dinal measures of all of the PSA isoforms were sig-
nificantly associated with biopsy upgrading, but
tPSA was not associated with upgrading. All of the
isoforms also showed improved discriminant accu-
racy compared to tPSA, with %[2]proPSA and phi
showing the highest concordance indexes for base-
line and longitudinal measures. For all biomarkers,
using longitudinal measures provided increased
discriminant accuracy compared to the measure at
baseline. %[2]proPSA and [2]proPSA/%fPSA showed
much larger hazard ratios for biopsy upgrading than
for biopsy reclassification. The other biomarkers
demonstrated similar hazard ratios for both out-
comes.
To explore why biopsy upgrading was better pre-
dicted by longitudinal than baseline biomarker val-
ues, we compared the absolute increase in each bio-
marker from baseline to last followup value for men
without vs with biopsy upgrading. For all biomark-
ers except %fPSA (where smaller values confer
higher risk), the magnitude of the change was larger
for men with upgrading. The difference was statis-
tically significant only for phi. We also evaluated
absolute biomarker change as a predictor in models
of biopsy upgrading, and none were statistically sig-
Table 3. Cox proportional hazards models and concordance
indices to predict reclassification by Gleason score upgrading
using baseline and longitudinal measurements
Cox Proportional Hazards Models
HR (95% CI) p Value C Index
Baseline:
tPSA 0.90 (0.77–1.05) 0.192 0.705
%fPSA 0.92 (0.86–0.99) 0.025 0.743
%[2]proPSA 4.02 (1.90–8.49) 0.0001 0.784
[2]proPSA/%fPSA 3.48 (1.26–9.59) 0.016 0.762
phi 1.06 (1.03–1.09) 0.0001 0.788
Longitudinal:
tPSA 0.95 (0.84–1.08) 0.445 0.771
%fPSA 0.93 (0.88–0.99) 0.025 0.786
%[2]proPSA 2.49 (1.51–4.10) 0.0001 0.832
[2]proPSA/%fPSA 2.49 (1.16–5.34) 0.019 0.786
phi 1.05 (1.02–1.07) 0.0001 0.820nificant (data not shown).DISCUSSION
In men with low risk prostate cancer, active surveil-
lance with delayed curative intervention has been
associated with a cause specific survival greater
than 97%.21 In accordance with these data, there
have been no deaths due to prostate cancer in our
active surveillance cohort.15 Furthermore, using a
pathology based definition of curability, preliminary
results from our cohort suggested that the opportu-
nity for cure, if necessary, was not sacrificed in those
who underwent treatment after a trial of active sur-
veillance compared to those who underwent imme-
diate treatment.22 Based on these and other similar
findings,23 active surveillance is considered a rea-
sonable management option for carefully selected
older men with low risk prostate cancer.
Despite these results, and the potential morbidity
associated with all forms of prostate cancer therapy,
the majority of low risk patients choose to undergo
immediate treatment rather than surveillance.24
Underuse of surveillance may be due to the lack of
biomarkers that can reliably predict which cases
will demonstrate reclassification on biopsy and may
subsequently require treatment. Moreover current
methods of monitoring disease (ie repeat biopsies)
are invasive, such that the discovery of a reliable
serum biomarker could improve the quality of care
for men undergoing surveillance.
Our group previously examined the relationship
between prostate cancer biomarkers and biopsy re-
sults during active surveillance.25,26 When used in
combination with other clinical variables, %fPSA at
diagnosis was associated with biopsy reclassifica-
tion,25 while baseline values of the molecular urine
marker PCA3 did not reliably predict reclassifica-
tion in the short term, although this study was lim-
ited by sample size and followup time.26 Another
promising new marker is proPSA, which has been
suggested as a means to improve the specificity of
PSA based screening.3
It was previously reported that the percentage of
proPSA measured in serum was useful for detecting
prostate cancer and reducing unnecessary biopsies
in men with tPSA between 2.5 and 4.0 ng/ml.6 An
additional study demonstrated similar results in a
larger population of men with PSA from 2 to 10
ng/ml.7 Furthermore, in men with a tPSA of 4 to 10
ng/ml, proPSA used in combination with PSA and
%fPSA increased the specificity for prostate cancer
detection more than any other parameter alone.27
More recently, retrospective28 and prospective10
multicenter studies as well as screening studies29
validated the usefulness of the [2]proPSA isoform
for cancer detection in the 2 or 2.5 to 10 ng/ml
tPSA range. In addition, recent studies have re-
ported on the Beckman Coulter phi, which combines
[2]proPSA IN ACTIVE SURVEILLANCE 1135[2]proPSA, fPSA and tPSA in a mathematical for-
mula. Jansen et al reported that phi had a higher
AUC for prostate cancer detection than tPSA or
%fPSA in 2 European screening populations.8 Sim-
ilarly the AUC for phi was higher than total or
%fPSA in a multicenter study of 892 men in which
an increasing phi was associated with a 4.7-fold
increased risk of prostate cancer.9
Several studies have aimed to clarify the poten-
tial role of proPSA in predicting prostate cancer
severity. In 2004 Catalona et al found that proPSA
levels were associated with high grade disease
(Gleason score 7 or greater) and/or extracapsular
tumor extension.11 In a prospective, multicenter
study %[2]proPSA increased with increasing bi-
opsy Gleason score and was higher in aggressive
cancers.10 The relationship between phi and Glea-
son score has been mixed, with no association ob-
served in the European cohorts8 and an increased
risk of Gleason score 4  3  7 at biopsy with
increasing phi observed in a recent multicenter
study.9
These data suggest that proPSA, in conjunction
with other biomarkers, may offer valuable diagnos-
tic and prognostic information. Nevertheless, there
are limited data on the usefulness of proPSA in
monitoring men on active surveillance. In a previous
study of 71 men in our active surveillance program,
tissue and serum [2]proPSA successfully identified
those who could safely remain on active surveil-
lance.12,13 Also, little is known regarding the role of
phi in active surveillance. Accordingly, we expanded
on previous findings by examining the association of
potential biomarkers and biopsy reclassification in a
larger population of men on active surveillance.
We believe that failing to identify high grade can-
cer poses the greatest risk to men on surveillance.
Thus, an improved ability to predict such cancers
could potentially decrease the risk associated with
surveillance. We found that baseline and longitudi-
nal measures of %fPSA, %[2]proPSA, [2]proPSA/
%fPSA and phi were significantly associated with
overall biopsy reclassification. Similar associations
were observed for reclassification based specifically
on Gleason score upgrading (Gleason score 7 or
greater). However, total PSA was not significantly
associated with biopsy reclassification.
For biopsy upgrading but not overall biopsy re-
classification, longitudinal biomarker measures pro-
vided greater predictive accuracy than using the
baseline measure only. The absolute biomarker
change between baseline and last biopsy was some-
what higher for men with biomarker upgrading than
for those without upgrading for all biomarkers ex-cept %fPSA, but the difference was significant only
for phi. It is possible that serial biomarker measure-
ments characterize the tumor grade phenotype more
accurately than a single baseline measure. However,
interpretation of this result is tentative as most
events of biopsy upgrading likely represent under
grading at the initial biopsy rather than true grade
progression.30 Given the cardinal role of tumor
grade as an indicator of suitability for active surveil-
lance, it will be important for larger independent
studies to validate whether longitudinal biomarker
sampling provides improved prediction of grade and,
if so, the optimal number and timing of samples.
A notable strength of our analysis is that all par-
ticipants were subject to a stringent and consistent
followup protocol. Furthermore, this study allowed
for the comparison of new serum markers with ob-
jective histological findings. Nonetheless, this study
is limited by its relatively small sample size and
number of end points achieved. Therefore, clinical
application should be reserved until these findings
can be validated in a larger cohort. Validation
should also explore threshold values yielding suffi-
cient sensitivity and specificity for potential clinical
use such that patients with abnormal values may
benefit from a more extensive preliminary evalua-
tion. As previously suggested,27 these markers must
also be studied in the context of other prostate can-
cer markers and may be most useful in a combined
model to improve predictive ability. In addition, the
associations observed in this study may vary in sur-
veillance programs using other eligibility and sur-
veillance criteria. Therefore, our analysis should not
be considered a formal assessment of a predictive
model, but rather that of an association between
selected markers and biopsy reclassification in this
cohort.
CONCLUSIONS
Baseline and longitudinal %[2]proPSA, [2]proPSA/
%fPSA and phi measurements were significantly
higher and %fPSA measurements were significantly
lower among men on active surveillance who demon-
strated biopsy reclassification due to extent of tumor
or Gleason upgrading on biopsy. Neither baseline nor
longitudinal tPSA measurements were significantly
associated with biopsy reclassification. Future studies
are warranted to better define the potential role of
these biomarkers and the optimal sampling scheme
for monitoring patients on active surveillance.
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